Morphogen-IX logo


Established 2015

Wei Li, PhD
Nick Morrell, MBBS, MD
Paul Upton, PhD

Morphogen-IX was founded in 2015 to identify and develop bone morphogenetic proteins, or BMPs, as a novel therapy for the treatment of pulmonary arterial hypertension, or PAH. PAH, a severe form of pulmonary hypertension, is a progressive life-limiting disease caused by the narrowing of small pulmonary arteries in the periphery of the lung.

The lead product candidate, MGX292, is a disease-modifying, protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of PAH.

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser